Get the Stockscreener App
69.63
0.26%
0.18
After Hours:
69.85
0.22
+0.32%
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca PLC stock is traded at $69.63, with a volume of 4.42M.
It is up +0.26% in the last 24 hours and down -4.46% over the past month.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$69.45
Open:
$69.965
24h Volume:
4.42M
Relative Volume:
0.88
Market Cap:
$228.90B
Revenue:
$54.98B
Net Income/Loss:
$7.77B
P/E Ratio:
27.96
EPS:
2.49
Net Cash Flow:
$9.14B
1W Performance:
-0.36%
1M Performance:
-4.46%
6M Performance:
+4.49%
1Y Performance:
-9.97%
1-Day Range:
$69.31
$70.02
1-Week Range:
$69.18
$72.01
52-Week Range:
$61.24
$87.67
Astrazeneca PLC Stock (AZN) Company Profile
Name
Astrazeneca PLC
Sector
Industry
Phone
44 20 3749 5000
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Compare AZN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
69.63 | 228.90B | 54.98B | 7.77B | 9.14B | 2.49 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca PLC Stock (AZN) Latest News
AstraZeneca (NASDAQ:AZN) PLC Stock Sees Institutional Growth on Nasdaq Composite - Kalkine Media
AstraZeneca and GSK fall after Trump renews pharma tariff threat - Proactive Investors
FTSE 100 Live: Stocks drop and oil spikes as Iran 'will not surrender', AstraZeneca falls on tariff threat - Proactive Investors
FTSE 100 Live: Stocks drop into the red, AstraZeneca and GSK fall on Trump tariff threat - Proactive Investors
AstraZeneca, GSK shares down after Trump threatens drug import tariffs By Investing.com - Investing.com Nigeria
FTSE 100 Live: Stocks edge higher as UK inflation eases, AstraZeneca and GSK fall - Proactive Investors
FTSE 100 Live: Stocks open higher as UK inflation eases, AstraZeneca and GSK fall - Proactive Investors
Astrazeneca makes $5.3B drug R&D pact with CSPC - BioWorld MedTech
AstraZeneca (AZN) Faces Potential Changes in Drug Advertising Ru - GuruFocus
Levi & Korsinsky Reminds AstraZeneca PLC Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025AZN - ACCESS Newswire
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
AstraZeneca’s ENHERTU Enters Pivotal Phase 3 Trial for Endometrial Cancer - Insider Monkey
AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica
Sector Update: Health Care Stocks Slide Late Afternoon - MarketScreener
AstraZeneca Inks Up To $5.3B AI Drug Deal With Chinese Firm - Law360
FIVE AT FIVE: FTSE 100 unsettled by Israel strike; AstraZeneca strikes $3.6bn Chinese AI deal - Proactive financial news
AstraZeneca and CSPC partner on AI drug research By Investing.com - Investing.com Nigeria
AstraZeneca and CSPC partner on AI drug research - Investing.com
AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal - Pharmaceutical Technology
AstraZeneca, CSPC Pharmaceuticals Enter Research Agreement - marketscreener.com
AstraZeneca signs research agreement with China's CSPC (AZN) - Seeking Alpha
AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans - BioPharma Dive
AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance - insights.citeline.com
AstraZeneca Inks Research Pact With China's CSPC Pharmaceuticals Focused On AI-Driven Research, Valued Up To $5.33 BillionAstraZeneca (NASDAQ:AZN) - Benzinga
AstraZeneca, Chinese bio firm sign $5.2B drug deal - breakingthenews.net
AstraZeneca signs $5.2bn deal to develop drugs for chronic disease with Chinese biotech - Financial Times
AstraZeneca Signs Nearly $5.3 Bln AI-enabled Research Deal With China's CSPC Pharma - Nasdaq
AstraZeneca (AZN) Enters Collaboration with CSPC for Novel Thera - GuruFocus
AstraZeneca: R&D agreement with CSPC Pharmaceuticals Group - MarketScreener
AstraZeneca bets big on AI and China with $3.6bn CSPC collaboration - Proactive financial news
AstraZeneca Enters Strategic Collaboration with CSPC Pharmaceuticals Group Limited - marketscreener.com
AstraZeneca, CSPC Ink Strategic Research Collaboration for AI-Driven Drug Discovery - marketscreener.com
The Zacks Analyst Blog Highlights Microsoft, AstraZeneca and BlackRock, Taylor Devices and Geospace Technologies - TradingView
AstraZeneca partners with CSPC in deal worth up to $5.33 billion - Investing.com Nigeria
AstraZeneca forms $5.3 billion AI drug discovery deal with CSPC - Investing.com
AstraZeneca signs AI research deal with China's CSPC for chronic diseases - MarketScreener
AstraZeneca agrees to research deal worth up to $5.22 billion with CSPC - Yahoo Finance
Astrazeneca Enters Collaboration Worth Up To $5.22 Bln With CSPC Pharmaceuticals - marketscreener.com
Top Stock Reports for Microsoft, AstraZeneca & BlackRock - Yahoo Finance
Chancery Tags AstraZeneca Unit For $180M 'Expectation' Loss - Law360
Leading bank sees AstraZeneca upside seen in hypertension drug, tempers lung cancer hopes - Proactive financial news
AstraZeneca CFO Donates Shares to Charity - TipRanks
AstraZeneca CFO donates shares to charity - Investing.com
AstraZeneca CFO donates shares to charity By Investing.com - Investing.com UK
REGAstraZeneca PLCDirector/PDMR Shareholding - TradingView
AstraZeneca (AZN): Vaccine Advisory Panel Reshuffled, Impact on Pharma Stocks | AZN Stock News - GuruFocus
UBS bullish on AstraZeneca’s baxdrostat, cautious on AVANZAR By Investing.com - Investing.com Nigeria
At a bargain-basement valuation now, is AstraZeneca’s share price impossible for me to ignore? - Yahoo
AstraZeneca (AZN) Watches CDC Vaccine Policy Developments | AZN Stock News - GuruFocus
AstraZeneca Unit Owes $180 Million-Plus in Syntimmune Case (1) - Bloomberg Law News
AstraZeneca, Lilly & J&J: Strategic Moves Powering SGLT‐2 - openPR.com
Astrazeneca PLC Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):